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Introduction
Atrial fibrillation (AF) confers a five-fold increased risk of 
ischemic stroke.1–4 A vitamin K antagonist (VKA) oral antico-
agulant (OAC) has been shown to be effective in preventing 
ischemic stroke in patients with AF.5 International guidelines 
recommend the use of oral anticoagulation to prevent stroke in 
such patients, except in those with a CHA2DS2-VASc 
score = 0.6,7 Nevertheless, studies have shown that VKA-OACs 
are overtly underused in clinical practice due to the difficulty in 
maintaining good anticoagulation control, as well as the fear of 
life-threatening bleeding complications.8–10
Dabigatran, the first commercially available non-vitamin 
K antagonist oral anticoagulant (NOAC), has revolutionized 
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Abstract
Background: Dabigatran, a non-vitamin K antagonist oral anticoagulant, has been shown to prevent stroke in patients with 
non-valvular atrial fibrillation. Nonetheless, studies show that 10%–30% of those prescribed dabigatran experience dyspepsia 
that may eventually lead to discontinuation of therapy and loss of clinical benefit.
Aim: To evaluate the gastrointestinal tolerability of dabigatran utilizing a validated questionnaire, as well as determining 
subsequent non-compliance and drug discontinuation.
Method: This is an observational study. All patients were assessed by a validated questionnaire, Hong Kong dyspepsia index, 
prior to drug prescription and again 4 weeks later.
Results: In this study, 115 patients with non-valvular atrial fibrillation (mean age: 74.6 ± 11.4 years; mean CHA2DS2-VASc 
score was 3.39 ± 1.59) were prescribed dabigatran. At baseline, the mean Hong Kong dyspepsia index was 12.9 ± 1.6 and nine 
patients had significant dyspepsia (Hong Kong dyspepsia index ⩾ 16). After 4 weeks, the mean Hong Kong dyspepsia index 
was similar at 12.6 ± 1.9 (p = 0.23). There was no change in Hong Kong dyspepsia index after initiation of dabigatran in 59 
(51.3%) patients, and improvement in 37 (32.2%). Only 19 (16.5%) patients had worsening of Hong Kong dyspepsia index, 
and among these 19 patients, only 1 patient (0.9%) discontinued dabigatran due to significant dyspepsia.
Conclusion: Worsening of dyspepsia with dabigatran 110 mg twice daily was uncommon with correct drug administration 
and clear instructions provided. Systematic assessment of dyspeptic symptoms using a validated questionnaire (i.e. Hong 
Kong dyspepsia index) before and after treatment initiation allows a more objective comparison of dyspeptic symptoms.
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the management of stroke prevention in AF. In the RE-LY 
(Randomized Evaluation of Long-term anticoagulation ther-
apY) study, dabigatran 110 mg twice daily was shown to be 
comparable to an adjusted dose of VKA in reducing stroke 
and systemic embolism, but associated with a lower risk of 
major bleeding, in particular intracranial hemorrhage.11,12 
Dabigatran 150 mg twice daily has been shown to be supe-
rior to VKA in reducing thromboembolic events, without an 
increased risk of major bleeding.11,13,14 Nonetheless, in the 
RE-LY study, 1 in 10 patients prescribed dabigatran devel-
oped dyspepsia that was twice as prevalent compared with 
those prescribed VKA and led to non-compliance and drug 
discontinuation.11
It has been reported that dyspepsia accounted for 30% of 
all dabigatran discontinuation in a “real-world” clinical 
setting,15 but there is a paucity of prospective data concerning 
the occurrence of upper gastrointestinal symptoms. Appropriate 
advice and pre-emptive measures such as advising patients to 
take the drug with meals may reduce the incidence of upper 
gastrointestinal symptoms and consequent discontinuation 
rate. In this study, we sought to assess the gastrointestinal toler-
ability of dabigatran, as well as the consequent non-compliance 
and drug termination in order to identify clinical parameters 
that could predict dabigatran intolerance.
Methods
Patients
Dabigatran-naïve patients who were ⩾18 years old, had doc-
umented non-valvular AF, a CHA2DS2-VASc score ⩾1, and 
preferred dabigatran to other available OACs were recruited 
to this study. Those who had significant valvular disease, 
previous valvular replacement, life expectancy <1 year, cre-
atinine clearance or estimated glomerular filtration rate 
<30 mL/min, pregnancy or pregnancy plan during the trial 
period, or any other medical condition that rendered the 
patient unsuitable for dabigatran were excluded.
Study design
This was a single-center, observational study conducted at 
Queen Mary Hospital, Hong Kong, between 1 January 2014 
and 31 December 2014 that evaluated the upper gastrointesti-
nal symptoms upon initiation of dabigatran in patients with 
AF. The study complied with the Declaration of Helsinki and 
was approved by the locally appointed ethics committee. After 
enrollment, all patients were prescribed dabigatran 110 mg 
twice per day. They were instructed to take doses 12 h apart, 
with a meal, and then remain upright for at least 30 min. 
Demographic data including cardiovascular risk factors, med-
ications, and prior history of gastrointestinal pathologies were 
recorded at baseline. Individual ischemic stroke risk was cal-
culated at baseline using the CHA2DS2-VASc score (C: con-
gestive heart failure (1 point); H: hypertension (1 point); A2: 
age 65–74 years (1 point) and age ⩾ 75 years (2 points); D: 
diabetes mellitus (1 point); S: prior stroke or transient ischemic 
attack (2 points); VA: vascular disease (1 point); and Sc: sex 
category - female (1 point) scores as described in recent 
guidelines).6,7 Symptoms of dyspepsia were quantified before 
and 4 weeks after initiation of dabigatran using a previously 
validated questionnaire, the Hong Kong dyspepsia index 
(HKDI).16,17 Briefly, the index comprises questions about 12 
symptoms (epigastric pain, upper abdominal bloating, upper 
abdominal dull ache, epigastric pain before meals, epigastric 
pain when anxious, vomiting, nausea, belching, acid regurgi-
tation, heartburn, feeling of acidity in the stomach, and loss of 
appetite) that are graded on a five-point Likert scale: 1 (none), 
no symptoms; 2 (mild), symptoms can be easily ignored; 3 
(moderate), awareness of symptoms but easily tolerated; 4 
(severe), symptoms sufficient to cause interference with nor-
mal activity; and 5 (incapacitating), incapacitating symptoms 
with an inability to perform daily activities and/or require days 
off work. The index has been previously demonstrated to be 
discriminative between dyspeptic patients and controls (HKDI 
⩾ 16).16 The serial change in HKDI correlated well with 
improvement and worsening of dyspepsia symptoms after 
therapeutic intervention (Kendall’s τ = 0.21, p = 0.02). The pri-
mary endpoint of this study was the change in HKDI before 
and 4 weeks after initiation of dabigatran. The secondary end-
point was dabigatran discontinuation within 4 weeks.
Statistical analysis
Continuous variables are expressed as mean ± standard devi-
ation. Categorical variables are presented in frequency 
tables. Statistical comparisons were performed using 
Student’s t-test or Fisher’s exact test, as appropriate. The 
change in HKDI scores from immediately before to 4 weeks 
after initiation of dabigatran was assessed by paired-sample 
t-test. Calculations were performed using SPSS software 
(version 21.0). A p-value <0.05 was considered statistically 
significant.
Result
A total of 115 patients with non-valvular AF were recruited 
in this study. Table 1 summarizes their clinical characteris-
tics. The mean age was 74.6 ± 11.4 years, and more than 50% 
of patients were ⩾ 75 years. The mean CHA2DS2-VASc 
score was 3.39 ± 1.59. Hypertension was present in 80 
(69.6%) patients, diabetes mellitus in 30 patients (26.1%), 
and history of ischemic stroke or transient ischemic attack in 
26 (14.8%). Approximately one-third of patients were pre-
scribed warfarin and another third were on aspirin prior to 
initiation of dabigatran. In addition, five patients had a past 
history of peptic ulcer (4.3%), four patients had gastritis 
(3.5%), one had a gastric polyp (0.9%), and one had a gastro-
intestinal stromal tumor (0.9%).
 at University College London on September 5, 2016smo.sagepub.comDownloaded from 
Chan et al. 3
At baseline, the mean HKDI was 12.9 ± 1.6 with a high 
level ⩾16 present in nine patients (7.8%), that is, significant 
dyspepsia. A concomitant proton pump inhibitor was pre-
scribed for 47 (40.9%) patients and a histamine-2 (H2) 
antagonist for 28 (24.3%) patients. No patient was newly 
commenced on either proton pump inhibitor or H2 antago-
nist in between these two HKDI questionnaires. After 
4 weeks of dabigatran therapy, the mean HKDI was 12.6 ± 1.9, 
not significantly different to the baseline (p = 0.23, Figure 1). 
There was no change in HKDI in 59 (51.3%) patients, 
improvement in 37 (32.2%), and worsening of HKDI in only 
19 (16.5%) patients. Of note, the number of patients with 
significant dyspepsia, that is, HKDI ⩾ 16, reduced from 9 
(7.8%) to 4 (3.5%) after initiation of dabigatran. Only 1 
patient (0.9%) who had a past history of duodenal ulcer dis-
continued dabigatran due to significant dyspepsia despite 
concomitant use of a proton pump inhibitor. During the 
4-week study period, there was no gastrointestinal bleeding 
or other bleeding episode in our study population.
Table 2 compares the baseline characteristics between 
patients with and without worsening of HKDI after initiation 
of dabigatran. Compared with those without worsening of 
HKDI, patients with worsening HKDI score were more likely 
to be female (43.8% vs 68.4%, p = 0.05). There was no sig-
nificant difference in the age, renal function, co-morbidities, 
baseline HKDI, past history of gastrointestinal disease, or 
concomitant prescription of a proton pump inhibitor or H2 
blocker between the two groups of patients (all with p ⩾ 0.05).
Discussion
In this study, we evaluated the gastrointestinal tolerance of 
dabigatran in patients who were naïve to dabigatran. Most 
patients were prescribed either a proton pump inhibitor 
(40.9%) or a H2 antagonist (24.3%). The HKDI was adminis-
tered to enable an objective evaluation of dyspeptic symp-
toms prior to and 4 weeks after the use of dabigatran. Our 
study showed that when systematically assessed by the 
HKDI, worsening of dyspepsia with dabigatran 110 mg 
twice daily was not common, and drug discontinuation due to 
gastrointestinal symptoms was infrequently encountered. 
Although previous studies including the RE-LY trial and real-
world cohorts showed a high incidence of “dyspepsia,”11,15,18 
this phenomenon was not observed in this study. Of note, the 
definition of “dyspepsia” employed in these previous studies 
was less clear and none systematically assessed the occur-
rence and severity of dyspeptic symptoms before and after 
initiation of dabigatran therapy.11,15,18 Patients are generally 
referred with the description of chronic or recurrent pain or 
discomfort centered in the upper abdomen,19 thus assessment 
of dyspepsia is largely based on patient reports, rather than 
physiological or laboratory parameters.16 In this study, we 
employed a validated questionnaire that comprised the rat-
ings of 12 relevant dyspeptic symptoms to quantify the pres-
ence and severity of dyspepsia before and after initiation of 
dabigatran therapy.16 Interestingly, with the use of a validated 
questionnaire, we found that fewer patients reported a wors-
ening of dyspeptic symptoms after initiation of dabigatran. 
This is in line with the results of a recently published Danish 
cohort that showed that dabigatran was not associated with 
increased hospitalization for dyspepsia-like diagnosis, an 
objective outcome measure.20 Of note, only one patient 
(0.9%) in this study discontinued dabigatran due to signifi-
cant dyspepsia despite concomitant use of a proton pump 
inhibitor. The previous findings of a high incidence of dys-
pepsia associated with the use of dabigatran may be related to 
the lack of systematic symptom assessment. Pre-existing dys-
pepsia was not recognized or documented with consequent 
injudicious attribution of dyspeptic symptoms to the use of 
Table 1. Baseline characteristics of the entire study population.
All (n = 115)
Age (years)
 Mean age 74.6 ± 11.4
 65–74 34 (29.6)
 ⩾ 75 62 (53.9)
Female, n (%) 55 (47.8)
Hypertension, n (%) 80 (69.6)
Diabetes mellitus, n (%) 30 (26.1)
Coronary artery disease, n (%) 13 (11.3)
Prior myocardial infarction, n (%) 6 (5.2)
Hypertrophic cardiomyopathy, n (%) 5 (4.3)
Heart failure, n (%) 26 (22.6)
Peripheral artery disease, n (%) 1 (0.9)
Stroke/transient ischemic attack (TIA), n (%) 17 (14.8)
Prior gastrointestinal bleeding, n (%) 2 (1.7)
Mean CHA2DS2-VASc 3.39 ± 1.59
Estimated glomerular filtration rate, n (%) 66.3 ± 15.2 mL/min
Previous warfarin use, n (%) 39 (33.9)
Previous aspirin use, n (%) 37 (32.2)
Figure 1. Scatter plot of Hong Kong dyspepsia index at baseline 
and 4 weeks after initiation of dabigatran. The red dashed line 
dented the cutoff (⩾16) for significant dyspepsia.16
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dabigatran, rather than a true increase in the incidence or 
severity of dyspepsia with dabigatran itself.
Another explanation of our results is the focused educa-
tion of patients about correct administration of dabigatran. 
Although there is no evidence regarding clinical manage-
ment of upper gastrointestinal symptoms related to dabi-
gatran, data from the RE-LY study have shown that taking 
dabigatran with two glasses of water or with food and 
remaining upright for at least 30 min afterwards are reason-
able measures to reduce drug-related dyspepsia.21 The dura-
tion of our study lasted only 4 weeks. Although data from 
previous studies have suggested that dyspepsia is more likely 
to occur early after initiation of dabigatran,20,22 it remains 
possible that more patients will develop worsening of dys-
pepsia with time. In addition, the impact of routine use of a 
proton pump inhibitor or H2 antagonist for patients pre-
scribed dabigatran could not be assessed from this study, and 
since such practice is becoming more common, it is possible 
that fewer patients will experience dyspepsia. Finally, we 
only studied dabigatran at a lower dose of 110 mg twice 
daily. Previous studies have reported no increase in non-
bleeding gastrointestinal adverse events when dabigatran 
dose was increased to 150 mg twice daily.20,21
Limitations
First, this was a single-center study in an Asian population. 
Due to differences in genetic and environmental factors that 
may contribute to dyspeptic symptoms, our results may not 
be generalized to patients of the other ethnicities. Second, we 
studied a single dose of dabigatran, 110 mg twice daily. The 
gastrointestinal effects associated with dabigatran 150 mg 
twice daily remain uncertain. Third, our study lasted for 
4 weeks. Longer follow up will be needed to identify those 
who develop worsening of dyspeptic symptoms late after ini-
tiation of dabigatran therapy. Finally, the prescription of a 
proton pump inhibitor or H2 antagonist was the individual 
decision of the physician and not randomized.
Conclusion
Our study showed that with correct administration, worsen-
ing of dyspepsia with dabigatran 110 mg twice daily was 
uncommon. Patients should be given instructions regarding 
administration of dabigatran at the time of treatment initia-
tion and with regular reinforcement thereafter. Systematic 
assessment of dyspeptic symptoms using a validated ques-
tionnaire before and after treatment initiation enables a more 
objective comparison of symptoms and may prevent unnec-
essary drug discontinuation.
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Table 2. Baseline characteristics of patients with and without worsening HKDI 4 weeks after initiation of dabigatran.
Patients without 
worsening HKDI (n = 96)
Patients with worsening 
HKDI (n = 19)
p-value
Mean age, (years) 74.1 ± 11.8 76.9 ± 8.8 0.33
Female, n (%) 42 (43.8) 13 (68.4) 0.05*
Hypertension, n (%) 63 (65.6) 17 (89.5) 0.05
Diabetes mellitus, n (%) 24 (25.0) 6 (31.6) 0.55
Prior myocardial infarction, n (%) 5 (5.2) 1 (5.3) 1.00
Hypertrophic cardiomyopathy, n (%) 4 (4.2) 1 (5.3) 1.00
Heart failure, n (%) 21 (21.9) 5 (26.3) 0.67
Stroke/transient ischemic attack (TIA), n (%) 15 (15.6) 2 (10.5) 0.73
Prior gastrointestinal bleeding, n (%) 1 (1.0) 1 (5.3) 0.30
Prior upper gastrointestinal pathology, n (%) 9 (9.4) 3 (15.8) 0.42
Baseline HKDI⩾ 16 9 (9.4) 0 (0) 0.35
Mean CHA2DS2-VASc 3.28 ± 1.63 3.95 ± 1.22 0.10
Estimated glomerular filtration rate (mL/min) 66.8 ± 15.0 63.3 ± 16.0 0.37
Previous warfarin use, n (%) 34 (35.4) 5 (26.3) 0.44
Previous aspirin use, n (%) 30 (31.3) 7 (36.8) 0.63
Concomitant proton pump inhibitor, n (%) 37 (38.5) 10 (52.6) 0.25
Concomitant H2 blocker, n (%) 24 (25.0) 4 (21.1) 0.71
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